Neuroendocrine testing in electroconvulsive therapy.
Dysregulation of specific neuroendocrine axes is seen frequently in patients with depressive disorder. Electroconvulsive therapy (ECT) causes both acute and chronic changes in numerous neuroendocrine parameters. The measurement of serum and cerebrospinal levels of hormones as well as the development of specific challenge tests have allowed the identification of potential state-specific markers for depression. These markers offer the potential for predicting both outcomes of treatment with ECT and long-term prognosis.
Kamil
R
R
Mood Disorders Program, Clarke Institute of Psychiatry, University of Toronto, Ontario, Canada.
Joffe
R T
RT
D004565:Electroconvulsive Therapy; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism; D009481:Neurophysins / Q000097:blood; D009490:Neurosecretory Systems / Q000378:metabolism*; D010913:Pituitary-Adrenal System / Q000378:metabolism; D011388:Prolactin / Q000097:blood; D013961:Thyroid Gland / Q000378:metabolism
D009481:Neurophysins; D011388:Prolactin; D013006:Growth Hormone